Table 2.

E7 antibody trend predicts cancer recurrence or progression to mortality among HPV-associated HNC patients.

		Number of patients (%)	Cancer recurrence or progression to mortality	No cancer recurrence or progression to mortality	P-value
p16+ HNC patients		39	11	27
E7 antibody trend among p16 positive patients	Positive with increasing trend	4 (10)	4	0
	Positive with decreasing trend	19 (50)	5	14
	Negative	16 (40)	2	14	P = .004(∗∗)

Contingency table of HPV-associated HNC patients' immune response trend in consecutive clinical visits throughout the treatment. The Fisher's exact test with Freeman-Halton extension is used for significance testing (∗∗ = p ≤ .01).